Compare SEGG & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEGG | PHGE |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Israel |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.9M |
| IPO Year | 2023 | N/A |
| Metric | SEGG | PHGE |
|---|---|---|
| Price | $1.02 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | N/A | ★ 128.8K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.50 |
| 52 Week High | N/A | $22.06 |
| Indicator | SEGG | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 47.16 |
| Support Level | $0.84 | $1.50 |
| Resistance Level | $0.99 | $2.35 |
| Average True Range (ATR) | 0.17 | 0.41 |
| MACD | 0.06 | -0.17 |
| Stochastic Oscillator | 26.40 | 18.62 |
Lottery.com Inc is a provider of domestic and international lottery products and services. As an independent third-party lottery game service, the Company offers a platform that it developed and operates to enable the remote purchase of legally sanctioned lottery games in the U.S. and abroad. The Company's revenue-generating activities are focused on (i) offering the Platform via the Lottery.com app and its websites to users located in the U.S. and international jurisdictions where the sale of lottery games is legal and its services are enabled for the remote purchase of legally sanctioned lottery games; (ii) offering an internally developed, created and operated business-to-business application programming interface of the Platform to enable commercial partners in permitted U.S.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).